ci 994 and melphalan
ci 994 has been researched along with melphalan in 2 studies
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Albella, B; Bueren, JA; Keyes, KA; LoRusso, PM; Parchment, RE | 1 |
| Albella, B; Bueren, JA; Keyes, KA; Parchment, RE; Segovia, JC | 1 |
Other Studies
2 other study(ies) available for ci 994 and melphalan
| Article | Year |
|---|---|
Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyond.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Blood Cell Count; Blood Platelets; Bone Marrow; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Melphalan; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neutropenia; Neutrophils; Phenylenediamines; Random Allocation; Stem Cells; Time Factors | 2000 |
Latent hematopoietic stem cell toxicity associated with protracted drug administration.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzamides; Bone Marrow; Colony-Forming Units Assay; Crosses, Genetic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematopoiesis; Hematopoietic Stem Cells; Injections, Intraperitoneal; Male; Melphalan; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Phenylenediamines; Time Factors | 2001 |